MDCX Medicus Pharma Ltd. Common Stock
USHealthcareAs of 2026-08-24
Why MDCX matters now
Medicus Pharma Ltd. Common Stock (MDCX) is a US stock in Healthcare. The latest InvestLog snapshot shows $0.26 with -5.30% on the session and $5.7M in market capitalization; recent performance reads 1-month +64.57% and YTD -70.10%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-6.6M, and EPS of $-0.22. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -232.1%.
The latest indexable market news headline is "Medicus Pharma advances pipeline during Q2 with key milestones" from Proactive Investors.
Additional event context on this page matters because analyst consensus is Buy with a median target of $—; recent insider activity includes Ashton William filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
10.19
P/S
0.00
EV/EBITDA
-0.10
DCF Value
$0.08
FCF Yield
-232.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-4086.3%
ROA
-497.3%
ROIC
-2193.3%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-6.6M | $-0.22 |
| Q4 2025 | $0.00 | $-8.2M | $-0.43 |
| FY 2025 | $0.00 | $-25.4M | $-1.96 |
| Q3 2025 | $0.00 | $-16.0M | $-1.12 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$—
Target (Median)
$—
Target Range
$— - $—
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
CA
Exchange
—
Beta
-0.46
Medicus Pharma Ltd., a biotechnology and life sciences enterprise, is dedicated to expediting the progression of innovative and groundbreaking medical treatments through their clinical development phases. A primary focus for the company is the creation of non-surgical solutions specifically targeting dermatological malignancies.